+49 30 648 35 164 service@chameleon-pharma.com

Chinese Pharma and Healthcare Market Opportunities Post COVID-19

While there’s no telling exactly when the COVID-19 crisis will end, there is one thing for certain; it will end eventually, and recovery may be more abrupt than expected in China.

Most industries in China have been gravely affected by the ongoing pandemic and companies have been scrambling to quickly adapt to the “new normal”. However, knowing that the crisis will eventually come to an end, it is important to consider the next steps for your businesses to look forward to opportunities that can help your business grow. As China begins its recovery, here are some trends we can expect in other parts of the world as well.

Increased Healthcare Spending

Considering the overall pharma and healthcare industry, the pandemic has revealed both the strengths and weaknesses of healthcare systems around the world. In China, the exposure of the weaknesses of healthcare infrastructure has propelled investment in this sector. We can expect that there will be substantial opportunities for medical device producers, healthcare delivery companies, traditional medicine and homeopathic companies, to name a few.

Greater Focus on Employee Health and Wellness

Employee health and wellness will also be a point of focus in the coming months. Implementing new health policies will be crucial in countries that have succeeded in flattening the curve in order to prevent the second wave of the disease. For example, the implementation of flexible working arrangement policies and employee health tracking.

The Rise of Digital Health

Digital health services are relatively new but considering what we have observed during this pandemic, they could easily become one of the largest areas of potential growth within the healthcare sector. In one instance, a Chinese healthcare app called Ping An Good Doctor reportedly saw a 900% increase in new users in response to the COVID-19 pandemic.

 

 

Featured image: Photo by Li Yang on Unsplash 

Contact us

14 + 10 =

Related Posts

Meet CPC at expopharm Munich 2026: Explore Pharmacy and

Meet CPC at expopharm Munich 2026: Explore Pharmacy and

Meet Chameleon Pharma Consulting CEO Reiner Christensen at expopharm Munich from 15–17 September 2026. Arrange an individual meeting to discuss pharmacy trends, international market entry, partner identification, and consumer healthcare opportunities.

Mexico’s New Fast-Track Drug & Medical Device Registration

Mexico’s New Fast-Track Drug & Medical Device Registration

Mexico is reshaping its COFEPRIS registration system with a new abbreviated Reliance pathway for eligible drugs and Medical Devices. With review targets of 45 business days for medicines and CPC Fast-Track registration strategies targeting approximately 10–15 months, the new framework creates important opportunities for faster market entry.

Meet Chameleon Pharma Consulting at CPHI Milan 2026

Meet Chameleon Pharma Consulting at CPHI Milan 2026

Meet Chameleon Pharma Consulting CEO Reiner Christensen at CPHI Milan from 6–8 October 2026. Schedule a meeting to discuss international market entry, licensing, partner identification, and growth opportunities for your pharma or consumer healthcare business.

Our services

i

International Company Partner Identification

Licensing and
M&A

Product Potential & Country Analysis

International Business & Market Entry

U

Pharma Regulatory & Registration

Pharma Executive
Search

International Strategy & Analysis

Market Reports and Analysis